HR was described in breast and ovarian cancer and leads to the complete inactivation of BRCA1 and BRCA2. Specific patterns of SVs, in particular, short tandem duplications and deletions, were found in BRCA1 and BRCA2 cancer genomes, respectively (Nik-Zainal et al., 2016) (Figure 2D). This evidence concerns the gene BRCA1 and ovarian carcinoma.